NCT07173556View on ClinicalTrials.gov

A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

October 31, 2028

Conditions

Advanced Breast Cancer

Interventions

DRUG

QLC1401

CDK4/6 inhibitors: Palbociclib, Abemaciclib, Ribociclib

DRUG

QLC1401

mTOR inhibitors: Everolimus

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY